Human gene therapy trials: cautious optimism
Alpha-1 antitrypsin (AAT) is the most prominent endogenous serine proteinase inhibitor (SERPIN) in humans. An inherited AAT deficiency is second in prevalence only to cystic fibrosis among inherited diseases of the lungs. The genetic abnormality is thoroughly described, current therapy is suboptimal and multiple vectors capable of delivering the normal AAT gene in vivo have been developed. In addition, unlike the cystic fibrosis transmembrane conductance regulator, AAT is a secreted protein so that gene therapy should be less demanding of the technology. However, in contrast to the situation with cystic fibrosis, there have been few clinical trials of gene therapy with AAT. There are currently no active AAT gene therapy trials in progress.
A general surrogate criterion for efficacy of AAT gene therapy has been achieving 'therapeutic' concentrations (that is approaching normal) in circulating blood or (receiving more emphasis) in bronchoalveolar lavage fluid. If the goal is to reproduce normal physiology, production and secretion of sufficient amounts of normal AAT protein by the liver to mimic the normal condition, those criteria are appropriate. The criteria are based primarily on the rationale used to approve AAT protein for clinical use as an orphan drug without proven effect on the course of the disease. Although some of the more recent technologies are approaching levels of gene delivery and expression sufficient to meet these criteria, recent evidence suggests that if the AAT gene is expressed in the lungs (ie at the site of the disease for which the therapy is intended), the level of AAT transgene expression required may be less than previously thought.
There are two clinical trials in humans either imminent or nearly so that propose delivery of a normal AAT transgene to the respiratory tract of humans. One proposed study is based on animal studies indicating that the normal AAT gene delivered in an adenoassociated viral vector (AAV-AAT) can produce prolonged 'therapeutic' serum concentrations of the normal protein (see discussion of the animal studies below).
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This proposal would inject AAV-AAT intramuscularly with the goal of achieving normal blood AAT concentrations. 2 Studies would be done in 8-12 relatively healthy subjects with the common PiZZ phenotype AAT deficiency. According to the information on the Alpha-1 web site, 2 these studies are nearing approval by the appropriate regulatory agencies and should begin soon.
The one reported study in human subjects used an unmodified cationic liposome (DOTMA:DOPE) and a plasmid vector containing the normal human AAT gene driven by a CMV promoter. 3 In this study, the lipoplex was instilled into one nostril of five subjects with ZZ phenotype AAT deficiency, with the contralateral nostril serving as a control. AAT concentrations were measured in serial samples of nasal lavage fluid. As shown in Figure 1 , AAT concentrations increased significantly in the transfected nostril, peaking on day 5 after transfection and returning to baseline by day 14. The mean peak AAT concentration in the transfected nostril in these five subjects was about one third the normal level (Figure 2 ). Those studies demonstrate that lipoplex technology can deliver a normal AAT gene to human respiratory epithelium in vivo, but delivery to the entire lung presents other challenges.
A new proposal is to conduct a similar investigation in subjects with cystic fibrosis where lung destruction may be partly attributable to the presence of large amounts of protease, but to extend the study to determine the effects of repeated dosing of the lipoplex. Two subjects have completed this protocol, but the study is now on clinical hold by the FDA awaiting production of new plasmid and liposome reagents.
Lung-directed AAT gene transfer may be therapeutic without 'therapeutic' protein levels in body fluids: applications beyond AAT deficiency Proteolytic events are ubiquitous in both physiologic and pathologic processes. AAT is normally produced primarily in the liver, reaching the lung via the circulation. Since AAT is a relatively large hydrophilic protein, it is excluded from intracellular and other cryptic spaces where pathologic proteolytic events occur. If lung cells are made to produce AAT, the antiproteolytic activity might locate inside cells where it is produced as well as in interstitial and intercellular spaces not usually available to circulating AAT. Thus, locally expressed AAT might have potentially therapeutic activities similar to those of small molecule antiproteases.
Figure 2 summarizes data from nasal lavage fluid in studies on AAT-deficient subjects who had a single nostril transfected with a normal human AAT gene delivered as a lipoplex. 3 Shown are measurements of AAT and of interleukin-8, a proinflammatory cytokine measured in these studies as an indicator of inflammation. When on no therapy, AAT concentrations in nasal lavage fluid were very low as expected, and IL-8 concentrations were significantly elevated compared to Alpha-1 antitrypsin AA Stecenko and KL Brigham normal, indicating some level of continuing inflammation. While these subjects were receiving intravenous AAT protein therapy, nasal lavage fluid concentrations of AAT were in the normal range, but IL-8 levels remained elevated. In contrast, when nasal epithelium was expressing the normal AAT transgene, nasal lavage fluid AAT concentrations were only about one-third the normal mean, but IL-8 concentrations were normal. These findings suggest that if the normal AAT gene is expressed locally, it may not be necessary to achieve 'therapeutic' AAT concentrations in plasma or bronchoalveolar lavage fluid in order to have a therapeutic effect. In addition, the anti-inflammatory effect of local expression may expand the disease targets for this therapy to include a broad range of chronic lung diseases in which inflammation is a major part of the pathophysiology.
Strategies for
Human respiratory epithelium is not rich in the requisite specific cell receptors, so that adenoviral vectors are inefficient at delivering transgenes to the lungs of humans. 4 In addition, even replication-deficient adenoviruses cause an acute inflammatory response and immunity is common. Several strategies have been used in attempts to improve efficiency and decrease toxicity of these vectors.
One strategy to overcome pre-existing immunity is to employ species-specific adenoviral vectors in a heterologous species. This approach should diminish the issue of pre-existing immunity. An ovine adenoviral vector was used to deliver an AAT transgene to mice by intramuscular injection. 5 Moderate doses of the vector resulted in high serum AAT levels, and expression of the gene was limited to the site of injection, but expression was transient and viral DNA was rapidly cleared and was accompanied by a cellular immune response. Viral doses low enough to minimize the immune response still produced potentially therapeutic serum AAT levels (4100 ng/ml) and a second intramuscular injection produced serum AAT levels similar to the first. These studies address some of the problems limiting the clinical potential of adenoviral vectors, but requirements for long-term repeated dosing with unknown efficacy and safety are limitations to clinical application.
Although the bulk of work with liposomes as a technology for delivering genes in vivo has been with lipoplex formulations (plasmid-cationic liposome complexes), a recent report uses liposomes as an escort for an adenoviral vector. Yotdna et al 6 encapsulated adenoviral vectors into bilamellar DOTAP:chol liposomes with the hypothesis that the lipid-coated virus could enter cells independent of specific receptors and would also be unaffected by virus-specific antibodies. Adenoviral vectors expressing either the reporter gene, b-galactosidase, or the human alpha-1 antitrypsin gene were coated with liposomes and their transfection efficiency in cultured cells with and without adenoviral receptors was compared with uncoated vector. The liposome-viral complexes infected cells independent of receptors. The complexes also protected the virus from neutralization by human antisera. In mice, intravenous delivery of viral-liposome complexes expressing the AAT gene produced detectible serum AAT levels for up to 30 days (uncoated vector expressed for only about a week). The coated vector also expressed more exuberantly after a second dose delivered a month after the first. The acute inflammatory response (as measured by serum levels of IL-6) was significantly less in animals given the liposome-viral complex than those given the uncoated viral vector. More advanced formulations employing combinations of liposome and viral technologies for gene delivery may eventually be clinically useful.
Adeno-associated viral vectors have low toxicity and effectively deliver an AAT transgene in animals
As it becomes obvious that adenoviral vectors are less than optimal, other viral vectors are being explored. Adeno-associated virus (AAV) vectors have the advantage of apparent high in vivo transgene expression and low toxicity. A single injection of an AAV vector expressing the AAT gene into the liver can achieve potentially therapeutic serum AAT levels that persist for at least several weeks. 7 However, in order to achieve potentially therapeutic serum AAT levels with intramuscular injection, it is necessary to give fairly high doses of vector. A more efficient system is desirable both to minimize toxic potential and because production of AAV vector is complicated and expensive. In addition, AAT deficiency causes liver as well as lung disease. The liver disease results from aberrant intracellular trafficking of the misfolded mutant AAT protein. So, although the lung disease might be prevented by achieving sufficient extracellular AAT concentrations, correcting the liver disease will likely require expression of a normal AAT transgene in the majority of hepatic cells since suppression of synthesis of the abnormal protein by expressing the normal gene would only occur in cells expressing the normal transgene.
The group that undertook the original studies with intramuscular injection of an AAT-containing AAV vector now report studies in which such vectors were injected into the portal vein of adult mice. 7 They compared results to those with intravenous injection. They injected mice intravenously with an AAV construct containing the AAT gene driven by a CMV-b actin hybrid promoter at varying doses and followed serum AAT protein concentrations. There was a dose-related elevation in serum AAT with potentially therapeutic levels sustained for up to 50 weeks at the higher viral doses. Southern blot analysis of liver tissue indicated that the vector was predominantly episomal at an average density of 25 copies per cell. However, immunohistochemical analysis of liver tissue using an antibody specific for the human protein showed a patchy distribution of the protein and a relatively small fraction of cells (6.4%) containing the protein. There was no evidence of toxicity.
Alpha-1 antitrypsin AA Stecenko and KL Brigham AAV vectors appear to have some distinct advantages over adenoviral vectors. The lack of an acute inflammatory response, even on direct injection into the liver, and the prolonged expression of the normal AAT gene at levels sufficient to produce potentially therapeutic serum AAT concentrations are encouraging for possible treatment of the lung disease in AAT-deficient subjects. However, the efficacy of intraportal delivery of the normal AAT gene in an AAV vector for treating the liver disease of AAT deficiency will likely require strategies to increase the fraction of hepatocytes expressing the transgene.
Nonviral vectors can deliver a functioning AAT gene in vivo and can be designed to prolong transgene expression Nonviral vectors for gene therapy are limited by low efficiency of transgene expression and short duration of expression. They continue to be attractive, however, because plasmids are not human pathogens in any setting and therefore carry less potential for harm than most viral vectors. Recent studies attempt to address these issues.
There are several reasons for the short duration of expression of transgenes delivered to mammals in plasmid vectors. One reason is that plasmids do not replicate in mammalian cells so that host cell replication obligatorily dilutes the vector. However, plasmids can be constructed to include eukaryotic replication initiation sites that render them capable of replicating in cycle with replication of the host cell. Stoll et al 8 constructed a plasmid expression vector that contained the AAT gene and incorporated eucaryotic replication initiation sequences from Epstein-Barr virus, EBNA1 and its family of binding sites. After intravenous injection using the interesting technique of 'hydrodynamic injection' of the naked plasmid into mice, they found greater than 300 mg/ml of AAT in serum, and increased serum AAT concentrations were maintained for greater than 9 months after a single administration of the vector. Although it is well established that these vectors containing EBV eukaryotic replication initiation sequences undergo extrachromosomal replication in dividing cells in culture, the fact that essentially nondividing liver cells in vivo retain the expressing vector for long period of time is somewhat unexpected. The favorable safety profile of plasmid vectors over viral vectors makes these observations interesting as the technology for clinical application develops.
Intravenous injection of linear DNA encoding the AAT gene driven by an RSV promoter into mice is reported to achieve 10-100 fold higher serum AAT concentrations than similar administration of circular DNA with expression persisting for at least 9 months. 9 The administered DNA localized to the liver and rapidly formed large unintegrated concatemers. This physical form of the DNA may contribute to more exuberant and prolonged in vivo expression than seen with circular vectors. However, those results were obtained after rapid intravenous injection of 40 mg of DNA in 2 ml saline. Assuming a mouse of approximately 25 g, similar administration to a 50 kg human would require rapid intravenous injection of 80 mg of DNA in 4 l of saline, so that the clinical applicability of this approach is questionable at present.
The clinical potential of cationic liposome-plasmid complexes (lipoplexes) remains interesting because of their apparent safety, but their limitations are similar to those of other nonviral technologies. Dasi et al 10 covalently coupled an asialoglycoprotein (asialofetuin) ligand for a unique hepatocyte receptor to either cationic or anionic liposomes and administered lipoplexes containing these modified liposomes and a plasmid vector containing the AAT gene intravenously to mice. They produced serum AAT levels of 50-300 ng/ml that persisted for up to 12 months with DNA doses of 200 ng/mouse. The asialoglycoprotein conjugate conferred considerably greater efficacy than unmodified liposomes, either cationic or anionic.
RNA/DNA oligonucleotide (RDA)-directed repair of the defective AAT gene
Although not uniformly accepted as a valid approach to therapy, a newly reported technology under development may permit site-specific correction of a single base carried in a chromosome and therefore, in theory, provide a basis for correcting the most common genetic mutations leading to AAT deficiency. 11 This technology (designated Genoplasty (Valigen, Lawrenceville, NJ, USA)) uses RNA/DNA chimeric molecules with short targeting sequences that are completely homologous with the region of interest except for the single base to be corrected. These regions are thought to be recognized and corrected by the cell's endogenous DNA repair systems. In vivo feasibility of this technology has apparently been reported for some genes in mice, but application to AAT deficiency will require confirmation of the concept and developing efficient systems for delivering the chimeric molecules to the liver that is efficient enough to correct the requisite number of hepatocytes.
